On July 16, 2025, Lake Street analyst Frank Takkinen announced the initiation of coverage on AngioDynamics (ANGO, Financial), a healthcare technology company, with a "Buy" rating. This announcement marks the first coverage of AngioDynamics by Lake Street.
Alongside the "Buy" rating, Takkinen set a price target of $24.00 USD for AngioDynamics (ANGO, Financial). No prior price target was available, as this is the first such estimate provided by Lake Street for the company. The current rating and price target suggest a positive outlook for AngioDynamics (ANGO) in the stock market.
Investors and stakeholders are likely to closely monitor the performance of AngioDynamics (ANGO, Financial) following this new analyst coverage. The company's standing in the healthcare technology sector may draw increased attention due to this endorsement by Lake Street.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for AngioDynamics Inc (ANGO, Financial) is $15.67 with a high estimate of $16.00 and a low estimate of $15.00. The average target implies an upside of 82.38% from the current price of $8.59. More detailed estimate data can be found on the AngioDynamics Inc (ANGO) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, AngioDynamics Inc's (ANGO, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for AngioDynamics Inc (ANGO, Financial) in one year is $8.26, suggesting a downside of 3.84% from the current price of $8.59. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the AngioDynamics Inc (ANGO) Summary page.
